Sugentech Inc Cash Flow Conversion Efficiency
Sugentech Inc cash flow conversion efficiency. Based on the latest financial reports, Sugentech Inc (253840) has a cash flow conversion efficiency ratio of -0.064x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-4.39 Billion ≈ $-2.98 Million USD) by net assets (₩68.56 Billion ≈ $46.46 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Sugentech Inc (2017–2025)
Cash flow conversion efficiency of Sugentech Inc from 2017 to 2025. This chart illustrates how Sugentech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Sugentech Inc (253840) stock price for real-time trading data and today's change.
Sugentech Inc Cash Flow Conversion Ratio Explained
Sugentech Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Sugentech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sugentech Inc ranked by their cash flow conversion efficiency. Also see 253840 market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hunan Tyen Machinery Co Ltd B
SHG:900946
|
0.007x |
|
Hironic Co. Ltd
KQ:149980
|
0.042x |
|
Hanil Forging Industrial Co. Ltd
KQ:024740
|
0.097x |
|
Globalink Investment Inc
NASDAQ:GLLI
|
-0.010x |
|
Ihlas Haber Ajansi AS
IS:IHAAS
|
-0.228x |
|
4Mass SA
WAR:4MS
|
0.110x |
|
NAXS Nordic Access Buyout Fund AB
ST:NAXS
|
-0.002x |
|
Mangalam Organics Limited
NSE:MANORG
|
0.034x |
Annual Cash Flow Conversion Efficiency for Sugentech Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Sugentech Inc from 2017 to 2025. Review 253840 free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩76.54 Billion ≈ $51.87 Million |
₩-14.65 Billion ≈ $-9.93 Million |
-0.191x | -147.24% |
| 2024-12-31 | ₩97.13 Billion ≈ $65.82 Million |
₩-7.52 Billion ≈ $-5.09 Million |
-0.077x | +28.39% |
| 2023-12-31 | ₩112.45 Billion ≈ $76.21 Million |
₩-12.15 Billion ≈ $-8.24 Million |
-0.108x | -149.93% |
| 2022-12-31 | ₩140.58 Billion ≈ $95.27 Million |
₩30.43 Billion ≈ $20.62 Million |
0.216x | -44.04% |
| 2021-12-31 | ₩100.71 Billion ≈ $68.25 Million |
₩38.96 Billion ≈ $26.40 Million |
0.387x | +67.51% |
| 2020-12-31 | ₩63.11 Billion ≈ $42.77 Million |
₩14.57 Billion ≈ $9.87 Million |
0.231x | +239.92% |
| 2019-12-31 | ₩24.31 Billion ≈ $16.47 Million |
₩-4.01 Billion ≈ $-2.72 Million |
-0.165x | +18.61% |
| 2018-12-31 | ₩15.46 Billion ≈ $10.47 Million |
₩-3.13 Billion ≈ $-2.12 Million |
-0.203x | -831.42% |
| 2017-12-31 | ₩-32.81 Billion ≈ $-22.24 Million |
₩-909.59 Million ≈ $-616.42K |
0.028x | -- |
About Sugentech Inc
Sugentech Inc. develops and sells in-vitro diagnostic systems and products based on biotechnology, information technology, and nanotechnology in South Korea and internationally. The company offers lab tests, including systems and test items; and COVID-19 tests. It also provides point of care testing analyzers and test items for testing of influenza A/B, antibody test, COVID-19 and flu, SARS-CoV-2… Read more